| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 12, 2025 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 12, 2025 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2025 | $4.00 | Buy | Lake Street |
4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
vCLASTM Used to Treat Patients with No Satisfactory Approved Treatment and/or Failed RF or PFA Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the successful completion of 13 ventricular ablation procedures at leading institutions using the Company's proprietary Ultra-Low Temperature Ablation (ULTA) technology under Expanded Access authorization from the U.S. Food and Drug Administration (FDA). The procedures addressed recurrent, symptomatic ventricular tachycardia (VT) or premature ventricular contractions (PVC) in patients who had previously failed abl
Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be participating in the 38th Annual Roth Conference on March 23-24, 2026 in Laguna Niguel, CA and will be hosting one-on-one meetings with investors at the conference. For more information on the 38th Annual ROTH Conference, or to schedule a meeting with Adagio Medical management, please contact your ROTH representative or you may also email your request to [email protected]. About Adagio Medical Holdings, Inc. Adagio is a medical device company focused on developing and commerci
Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the TD Cowen 46th Annual Healthcare Conference on Tuesday, March 3, 2026 at 2:30 PM ET in Boston, MA. Presentation Information A live webcast and replay of the session will be accessible at https://event.summitcast.com or on the Company's website at https://investors.adagiomedical.com. About Adagio Medical Holdings, Inc. Adagio is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel,
Lake Street initiated coverage of Adagio Medical Holdings with a rating of Buy and set a new price target of $4.00
SCHEDULE 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)
SCHEDULE 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)
SCHEDULE 13G/A - Adagio Medical Holdings, Inc. (0002006986) (Subject)
Marie-Claude Jacques appointed Senior Vice President, Global Sales; Antwan Gipson joins as Senior Vice President, Manufacturing & Operations Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced two key additions to its senior leadership team: Marie-Claude Jacques as Senior Vice President, Global Sales and Antwan Gipson as Senior Vice President, Manufacturing and Operations. "These appointments represent a significant milestone as Adagio prepares for commercialization of our proprietary Ultra-Low Temperature Cardiac Ablation technology ("ULTC") for electrophys
Adagio Medical Holdings, Inc (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that Sean Salmon has been appointed to its Board of Directors. Mr. Salmon will also serve on the Company's Audit Committee and Compensation Committee. Mr. Salmon, 60, recently retired from Medtronic after a distinguished, 20+ year tenure during which he held multiple senior global leadership roles across the company's cardiovascular and diabetes businesses. Most recently, he served as Executive Vice President and President of Medtronic's Cardiovascular Portfolio, which includes the Cardiac Rhythm, Cardiac Abl
Continued Momentum Toward PMA Submission of ULTC Technologies Recent Financing Positions Company to Execute Growth Strategy Adagio Medical Holdings, Inc (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the third quarter ended September 30, 2025. Recent Business Highlights: Closed a private placement on October 20, 2025, with gross proceeds of up to $50 million, led by a syndicate of healthcare-dedicated institutional investors; upfront proceeds of approximately $19 million expected to fund FDA submission activities and ongoing next generation catheter deve
SC 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)
SC 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)